How Aegis Is Connecting Rare Disease Patients to Clinical Trials with AI

A Parent Shouldn't Need to Become a Medical Researcher

Imagine your child is diagnosed with a rare mitochondrial disorder. The doctor delivers the news carefully, explains that there are no approved treatments, and suggests you "look into" clinical trials. You go home. You open ClinicalTrials.gov. You are immediately confronted with 480,000 study listings, Boolean search fields, dense eligibility criteria written for clinicians, and no clear path forward.

Meanwhile, two states away, a Phase II trial is actively enrolling patients with exactly your child's genetic mutation. The research coordinator has been struggling to find eligible participants for eight months. The trial sponsor is watching their timeline slip. And your child — who is a perfect match — has no idea this trial exists.

This is not an edge case. This is the daily reality for millions of rare disease patients worldwide. And it's the problem that Aegis was built to solve.

The Scale of the Problem Is Staggering

Rare diseases are, collectively, not rare at all. There are over 7,000 known rare diseases affecting roughly 400 million people worldwide — more than the entire population of the United States. For approximately 95% of those conditions, there is no FDA-approved treatment. Clinical trials are not a last resort for these patients. They are often the only option.

The gap between "trials exist" and "patients find them" is enormous. Trial recruitment relies on a patchwork of physician awareness — which is inconsistent at best — fragmented patient advocacy groups, and a government database that was designed for researchers, not patients. The result: trials that enroll too slowly, miss their endpoints for reasons unrelated to the science, and sometimes get cancelled before they can deliver data that might help thousands of people.

What Aegis Does — And Why It's Different

Aegis is an AI-powered clinical trial matching platform built specifically for the complexity of rare diseases. It is not a search engine. It is not a filtered version of ClinicalTrials.gov. It is a matching engine that understands the nuanced, deeply specific eligibility criteria that define rare disease trials — and pre-qualifies patients against them before anyone picks up the phone.

Here's how it works:

1. Patient data ingestion: Aegis ingests health records, genetic test results, diagnosis codes, prior treatment history, and biomarker data in standardized formats. Patients or their caregivers can also self-report key information through a guided intake process.
2. Intelligent trial matching: The platform continuously pulls from a global database of active and upcoming rare disease clinical trials, parsing eligibility criteria — including specific genetic variants, mutation types, biomarker thresholds, prior therapy requirements, and geographic constraints — into machine-readable logic.
3. Pre-qualification at scale: Rather than returning a list of vaguely relevant trials, Aegis pre-qualifies patients against inclusion and exclusion criteria. The output isn't "here are 40 trials that mention your disease" — it's "here are 3 trials you likely qualify for, here's why, and here's how to take the next step."
4. Sponsor-side recruitment acceleration: For pharmaceutical and biotech sponsors running trials, Aegis works as an enrollment partner — identifying and surfacing qualified patients who have opted into the matching network, dramatically reducing the time from protocol activation to first patient enrolled.

Two Audiences. One Platform. One Mission.

Aegis serves two fundamentally different but deeply connected audiences, and its dual-sided model is part of what makes it powerful.

Patients and Caregivers

The primary beneficiary is the rare disease patient — or more often, the caregiver navigating a diagnosis on behalf of a child, a parent, or a partner. These are people who have often spent years searching for answers. They are medically engaged, highly motivated, and chronically underserved by existing infrastructure. Aegis gives them a tool that actually speaks their language, explains why they may or may not qualify for a specific trial, and helps them take a concrete next step rather than disappearing into a database.

Pharma and Biotech Sponsors

On the other side of the marketplace are the sponsors running rare disease trials. For a biotech company developing a therapy for a condition that affects 10,000 people globally, finding 50 eligible trial participants can feel impossible. Enrollment delays in rare disease trials routinely stretch 12–24 months beyond projections, burning cash and threatening program viability. Aegis provides sponsors with a qualified patient pipeline that no other recruitment channel can match — because it's built on actual patient data, not physician referrals or conference booths.

Why Now: A $26B Market at an Inflection Point

The rare disease clinical trial recruitment market is not a niche — it's a massive, underserved, and rapidly expanding opportunity. Global spending on rare disease drug development has surpassed $26 billion annually, driven by orphan drug incentives, breakthrough therapy designations, and the explosion of precision medicine and gene therapies that are, by definition, highly targeted to small populations.

Several converging forces make this the right moment for Aegis:

• Genetic testing is now mainstream. Whole exome sequencing costs less than $500. Millions of patients now have detailed genetic data sitting in records that have never been used to find them a trial.
• The pipeline is exploding. Over 700 gene therapies are currently in clinical development. The majority target rare genetic diseases. They all need patients — specific, genetically confirmed patients.
• Decentralized trials open geography. Remote monitoring and telehealth-enabled trial participation mean that geographic constraints that once disqualified patients are softening, dramatically expanding the eligible pool for any given trial site.
• AI is finally good enough. Parsing complex eligibility criteria — which can run to dozens of conditions involving genetic variants, treatment history, lab values, and comorbidities — was not solvable at scale before large language models and modern NLP. It is now.

Built with AI, End-to-End

Aegis was conceived and built on Artha, an AI platform that launches full companies from a single prompt. That origin matters — not just as a footnote, but as a signal about how the company operates. Aegis is AI-native from the ground up: the matching logic, the eligibility parsing engine, the patient-facing interface, and the sponsor dashboard were all built with AI as a core architectural assumption, not a bolted-on feature.

The ability to move from concept to deployed product at Artha's speed means Aegis could focus on the hardest parts of the problem — the clinical and regulatory nuance, the trust required to handle patient health data, the relationship-building with patient advocacy organizations — rather than spending months on infrastructure scaffolding.

"Every rare disease patient is searching for hope. Many clinical trials are searching for patients. Aegis connects the two."

What's Next for Aegis

The near-term roadmap for Aegis centers on deepening the matching engine's clinical intelligence — expanding the library of parseable eligibility criteria, integrating directly with major EHR systems so that matches surface inside clinical workflows rather than requiring patients to seek them out, and building advocacy group partnerships that bring existing, organized patient communities onto the platform.

Longer term, Aegis is positioned to become the infrastructure layer for rare disease trial enrollment globally — an always-on network that connects patient registries, genetic databases, research hospitals, and biotech sponsors into a single matching ecosystem. As gene therapy pipelines mature and the number of ultra-rare disease trials multiplies, the platform's value compounds with every new patient and every new trial added to the network.

The rare disease space is also, increasingly, where the most exciting science in medicine is happening. CRISPR-based therapies, RNA interference treatments, and next-generation AAV gene delivery are all targeting conditions that affect small, genetically defined populations. The trials for these treatments will need exactly the kind of precision matching infrastructure Aegis is building.

Build Your Own Company on Artha

Aegis was built on Artha — the AI platform that turns a founding idea into a launched company. From brand to product to go-to-market, Artha compresses what used to take months into days.

If you have a problem worth solving — in healthcare, in logistics, in finance, in anything — Artha can help you build it. Start with a single prompt. End with a company.